NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (OTCQB:RTRX) today announced that it has appointed
Jeffrey Paley, MD to its Board of Directors, effective November 15,
2013. This latest appointment brings the Company's Board to five members.
Commenting on today's news, Martin Shkreli, Founder, President and Chief
Executive Officer of Retrophin, noted, "We are delighted to welcome Jeff
as the newest member of our Board of Directors. Retrophin is currently
in an expansion phase and Jeff's extensive clinical expertise, as well
as his experience working with analysts and investors, will be
invaluable. We look forward to Jeff's joining our Board and for his help
in guiding Retrophin in further developing its Research and Development
program and pursuing strategic financings and acquisitions."
Dr. Paley has been an active clinician and consultant in the healthcare
industry for the past 18 years, during which time he has consulted for
over 30 analysts and portfolio managers in the biotechnology,
pharmaceutical, specialty pharmaceutical and medical technology arenas,
reviewing the clinical, preclinical and regulatory pedigrees of numerous
therapeutics and devices. Prior to his work for the buy-side, Dr. Paley
also consulted directly for several biotechnology and specialty
pharmaceutical companies. Dr. Paley founded Access Medical Associates,
PC in 2003, after spending five years on the full-time academic faculty
of Weill Cornell Medical College, where he served as Director of
Clinical Research at the Cornell Internal Medicine Associates. At Weill
Cornell, Dr. Paley was also a principal or co-principal investigator on
several studies of diabetes, hypertension, and cholesterol disorders,
including the landmark ACCORD study of intensive hyperglycemia,
hypertension and hyperlipidemia management. Additional clinical
interests include, sleep disorders, weight loss, adult attention-deficit
disorder, and cardiovascular disease prevention. Dr. Paley trained at
Harvard Medical School and completed a residency in Internal Medicine at
Massachusetts General Hospital.
About Retrophin
Retrophin is a pharmaceutical company focused on the discovery and
development of drugs for the treatment of debilitating and often
life-threatening diseases for which there are currently no viable
patient options. The Company is currently focused on several
catastrophic diseases affecting children, including Focal Segmental
Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated
Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy. Retrophin's
lead compound, RE-021, is scheduled to begin enrollment in a potentially
pivotal Phase 2 clinical trial for the treatment of FSGS during 2013.
For additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. In addition, expressions of our strategies, intentions or
plans are also forward-looking statements. Such forward-looking
statements are based on current expectations and involve inherent risks
and uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can
be guaranteed. Forward-looking statements in the press release should be
evaluated together with the many uncertainties that affect the Company's
business. You are cautioned not to place undue reliance on these
forward-looking statements as there are important factors that could
cause actual results to differ materially from those in forward-looking
statements, many of which are beyond our control. The Company undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise. Investors
are referred to the full discussion of risks and uncertainties as
included in the Company's filings with the Securities and Exchange
Commission.
Retrophin, Inc.
Marc Panoff, 646-546-3671
CFO
marc@retrophin.com
or
Investors
Rx
Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
Source: Retrophin, Inc.
News Provided by Acquire Media